In rodents, Amphista linked its BRD9 degrader AMX-883 to a significant improvement in survival and reduction in disease burden compared to Venclexta. Combining AMX-883 with Venclexta and azacitidine ...
NPM1 minimal residual disease (MRD) positivity before allogeneic hematopoietic cell transplantation is linked to higher relapse rates and lower overall survival in patients with acute myeloid leukemia ...
A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute ...
InvestorsHub on MSN
Evaxion Biotech gains after unveiling encouraging AML vaccine findings
Evaxion Biotech AS (NASDAQ:EVAX) climbed 4.2% in Monday’s premarket session after sharing new preclinical data supporting its ...
Panelists discuss how AML treatment has entered an exciting era of personalized medicine with increasing oral options and ...
Errata: Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis The classification of AML and therapeutic options are now largely driven ...
Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger ...
Creating a synthetic control arm from previous clinical trials: Application to establishing early end points as indicators of overall survival in acute myeloid leukemia (AML). This is an ASCO Meeting ...
SAN DIEGO — A polygenic score can link outcomes in Black pediatric patients with acute myeloid leukemia (AML) to genetic traits that arise more frequently in this population, new data reveal. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback